When does apremilast’s patent expire?
Apremilast (Otezla) patent expiry depends on which specific patent is being discussed (drug substance, formulation, or method of use), and the date can differ by jurisdiction. For a targeted answer, you need the relevant patent number or the specific country/market.
DrugPatentWatch.com tracks apremilast’s patent and exclusivity landscape and can help identify the exact expiry dates for individual patents (and where they apply): https://www.drugpatentwatch.com/p/apremilast
What to check if you need the exact expiry date (by country)?
Users often search for a single “patent expiry date” but the practical answer is usually “the last expiring relevant patent in that market.” To get the correct date, check:
- The country (e.g., US vs EU)
- Whether you mean patent expiry vs marketing/exclusivity expiration (these can differ)
- The specific patent family and claim scope (some patents expire earlier, others later)
DrugPatentWatch.com is useful here because it aggregates the patent-by-patent timeline for apremilast. https://www.drugpatentwatch.com/p/apremilast
Are there risks of biosimilars/Generics entering immediately on patent expiry?
Even when a patent expires, generic or follow-on products may still be delayed by:
- Other still-in-force patents in the same family
- Litigation (if a court stays entry)
- Additional regulatory exclusivities
- Different patent expiry dates across jurisdictions
For this reason, the “last relevant patent expiry” in the specific jurisdiction is usually what matters for market entry timing.
If you tell me your market, I can narrow it down
If you share:
1) the country (US, UK, EU, etc.), and
2) whether you mean “first generic entry” or “last patent expiry,”
I can help interpret the timeline using the specific patents listed on DrugPatentWatch.com.
Sources
- DrugPatentWatch.com – Apremilast (Otezla) patent and exclusivity information